华东医药：2025年第三季度报告（英文版）

HuadongMedicineCo.,Ltd.ThirdQuarterlyReport2025 TheCompany and all members of the Board of Directors hereby guarantee that theinformationpresentedinthisreportisauthentic,accurateandcompleteandfreeofanyfalse ImportantDeclaration: 1.TheBoardofDirectors,directorsandseniormanagersofHuadongMedicineCo.,Ltd.(hereinafterreferredtoasthe"Company")herebyguaranteethattheinformationpresentedintheReportisauthentic,accurateand 2.The Company's legal representative,the officer in charge of accounting,and the head of accountingdepartment(accountingsupervisor)herebydeclarethatthefinancialinformationinthisquarterlyreportis 3.HastheThirdQuarterlyFinancialAccountingReportbeenaudited? □YesNo Accordingto“StockListingRulesoftheShenzhenStockExchange”,iflistedcompanieshavebothChineseandotherlanguageversionofpublicnotice,theyshouldensurethecontentofbothversionsarethesame.Inthe I.KeyFinancialData (I)Keyaccountingdataandfinancialindicators DoestheCompanyneedtoretroactivelyadjustorrestatetheaccountingdataofpreviousyears? (II)Non-recurringprofitandlossitemsandamounts □ApplicableNotapplicable TheCompanyhasnootherspecificcircumstancesofprofitandlossitemsthatmeetthedefinitionofnon-recurringgainsand Anexplanationofthefactthatthenon-recurringgainandlossitemslistedintheExplanatoryAnnouncementNo.1onInformationDisclosurebyCompaniesthatOfferSecuritiestothePublic-Non-recurringGainsandLossesaredefinedasrecurringprofitand □ApplicableNotapplicable TheCompanydidnotdefinethenon-recurringgainandlossitemslistedintheExplanatoryAnnouncementNo.1onInformationDisclosurebyCompaniesthatOfferSecuritiestothePublic-Non-recurringGainsandLossesasrecurringprofitandlossitems. (III)Detailsandreasonsforchangesinkeyaccountingdataandfinancialindicators Unit:RMB10,000 II.ShareholderInformation (I)Totalnumberofcommonshareholders,numberofpreferredshareholderswithrestoredvotingrights □ApplicableNotapplicable Changein top 10 shareholders and top 10 shareholders holding tradable shares without restricted sale conditions due tolending/returningofsharesthroughrefinancingascomparedtothepreviousperiod □ApplicableNotapplicable (II)Totalnumberofpreferredshareholdersandshareholdinglistoftop10preferredshareholdersoftheCompany □ApplicableNotapplicable Ⅲ.OtherImportantMatters Applicable□Notapplicable (I)OverviewoftheCompany'soveralloperationsduringthereportingperiod Guidedby the principles of"promoting entrepreneurial spirit,deepening reforms,strengtheningorganizationalsystems,andcapturingdevelopmentopportunities",theCompany, FromJanuary to September 2025,the Company achieved total operating revenue ofRMB32.664billion,ayear-on-yearincreaseof3.77%;netprofitattributabletoshareholdersofthe RMB2.694billion,ayear-on-yearincreaseof8.53%. Specifically,inQ32025,theCompanyachievedtotaloperatingrevenueofRMB10.989billion,ayear-on-yearincreaseof4.53%;netprofitattributabletoshareholdersofthelisted TheCompany maintained stable and favorable overall operations.In Q4 2025,it willcontinueto rigorously execute the annual operational plan,efficiently advancing research, FromJanuarytoSeptember2025,theCompany'scorepharmaceuticalsubsidiary,ZhongmeiHuadong,sustainedastablegrowthtrendinoveralloperations,achievingoperatingrevenue(includingCSObusiness)ofRMB11.045billion,representingayear-on-yearincreaseof11.10%; Duringthe reporting period,the Company concentrated on the strategic priority ofcommercializinginnovativeproductsandactivelypursuedtheexpansionofitsmarketpresence.Theseinitiatives have begun to yield tangible results,with innovative products making an increasinglysignificantcontributiontorevenue.Specifically,fromJanuarytoSeptember2025,theCompany'srevenuefrominnovativeproductssalesandagencyservicestotaledRMB1.675 ZevorcabtageneAutoleucel Injection(trade name:Saikaize®),the CAR-T product exclusivelycommercializedbyZhongmeiHuadong,continuestobeincludedinanincreasingnumberoflocalgovernment-subsidizedinsuranceprogramsandcommercialinsuranceplans, partner,CARsgenTherapeutics,exceedingthetotalnumberofordersfortheentirepreviousyear.Furthermore,thefirstdomesticallyproducedUstekinumabInjection(tradename:SAILEXIN®)in theautoimmunefield,alongwiththeClass1newdruginthediabetesfield,GanagliflozinProlineTablets(tradename:Huiyoujing®),havesustainedrapidquarterlysalesgrowth,drivenbytheir Inaddition,theCompany'sexclusivepromotionofthenew1.5-generationPARPinhibitorSenaparibCapsules(tradename:Paishuning®)hasdeliveredstrongmarketperformance,withsalesdoubling month-on-month in the third quarter.Concurrently,the Company is activelypreparingfornationalmedicalinsuranceandcommercialinsurancenegotiationsforitsthreeinnovativeproducts—Paishuning®,ELAHERE®andSaikaize®inthefourthquarterof2025,aimingtoenhancepatientaccessibility,expandsaleschannels,andacceleratemarketpenetration. HuadongMedicine(Guizhou)PharmaceuticalCo.,Ltd.(hereinafterreferredtoas"GuizhouCorporation")focuses on achieving breakthroughs in its core products.By establishing a professional,self-operatedpromotionteam,itisfully